P
revious studies have reported a marked variation in the prevalence of microalbuminuria in type 2 diabetic patients ranging from 7 to 47% (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The variation could arise from ethnic/genetic differences in susceptibility (3) (4) (5) (6) (7) (8) (9) (10) (11) and from methodological issues for investigating the prevalence, such as small-sized populations (3, 12, 13) ; single clinic-based studies (8, 12) ; use of the dipstick method instead of quantitative determinations (4, 5) ; or only a single measurement of urinary albumin excretion (UAE) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) , whereas multiple measurements have been recommended for years (14) . In terms of investigating the prevalence of microalbuminuria in type 2 diabetic patients, we performed this study with the aim of investigating patients with a specific ethnicity (i.e., Japanese). The study had a large-sized population, a nationwide multicenter-based design, and a high proportion of data availability for clinical variables and for multiple measurements of UAE.
RESEARCH DESIGN AND METHODS
-A cross-sectional study was conducted that included 29 medical clinics (i.e., general practitioners) or general/university-affiliated hospitals from different areas in Japan, using the same software to incorporate patient records, as a working study group. Known as the Ja- (17) . Quantitative measurement of urinary albumin-tocreatinine ratio (ACR) at least once a year has been recommended (14, 16) . Eligible patients were those with at least one measurement of ACR if without proteinuria and/or serum creatinine if with persistent proteinuria. Those with nondiabetic kidney disease or elevated serum creatinine without proteinuria were excluded (n ϭ 75). Those with no measurement of ACR without proteinuria were not included (n ϭ 5,947). Thus, 8,897 patients were appropriate for the study.
Nephropathy was staged as follows (16) . Stage I: ACR Ͻ30 mg/g creatinine; stage II: ACR Ն30 and Ͻ300 mg/g creatinine (i.e., microalbuminuria); stage III: ACR Ͼ300 mg/g creatinine and/or persistent proteinuria with serum concentration of creatinine Ͻ176 mol/l (2.0 mg/ dl); stage IV: serum concentration of creatinine Ն176 mol/l with proteinuria; and stage V: being treated with dialysis. Nonfasting blood samples were obtained for measurements of A1C and serum concentrations of creatinine and lipids. The albumin concentration of random spot urine was determined by turbidimetric immunoassay and the creatinine by the enzymatic method. The geometric mean of two or three measurements of ACR was used. A1C was measured by highperformance liquid chromatography (normal range 4.3-5.8%). Results are given as means Ϯ SD. Comparison of clinical variables among the groups was performed by one-way ANOVA. P values Ͻ5% were considered to be significant. RESULTS -Prevalence of microalbuminuria and clinical nephropathy was 31.6 (95% CI 30.6 -32.6) and 10.5% (95% CI 9.9 -11.1), respectively, categorized by ACR (60% multiple and 37% single determination) and serum creatinine (Table 1) . Data availability was nearly 100%. Patients without measurement of ACR had similar clinical features; the mean age was 64 years, the distribution according to sex was 60/40% (men/ women), BMI 24.0 kg/m 2 , duration of diabetes 12 years, A1C 7.1%, systemic blood pressure 132/77 mmHg, and glomerular filtration rate 66.9 ml/min per 1.73 m 2 (2) . The fraction of patients on angiotensin receptor blocker (ARB) and/or ACE inhibitor was similar to that on calcium channel blocker, and the fraction of those on diuretics was low but increased at stages III and IV. The proportion of patients who achieved the treatment goal was 31% for A1C, 42% for blood pressure, and Ͼ50% for lipids. (28) 986 (35) 380 (58) 133 (55) 13 (38) Ͻ0.0001 (40) 356 (54) 166 (69) 17 (50) Ͻ0.0001
␤-blockers
504 (6) 220 (4) 194 (7) 56 (9) 30 (12) 4 (12) Ͻ0.0001
␣-blockers
254 (3) 105 (2) 73 (3) 37 (6) 35 (15) 4 (12) Ͻ0.0001
Diuretics 819 (9) 351 (7) 193 (7) 154 (23) 106 (44) 15 (44) Ͻ0.0001
Triglycerides (mmol/l) CONCLUSIONS -This nation-wide large-population study revealed that the prevalence of microalbuminuria in Japanese type 2 diabetic patients was 32%. The DEMAND (Developing Education on Microalbuminuria for Awareness of Renal and Cardiovascular Risk in Diabetes) study stated that the overall global prevalence of microalbuminuria among 24,151 patients with type 2 diabetes was 39% (5), and the MAP (MicroAlbuminuria Prevalence) study reported the prevalence at 40% among 5,549 Asian patients (4). These findings indicate that microalbuminuria is common. Our study is the second largest in terms of the number of subjects investigated and, furthermore, achieved high data availability, with 60% of multiple quantitative measurements for UAE, while other large-population studies performed single measurements by dipstick with 20 -40% of data-missing rates for A1C and blood pressure levels (4, 5) . The mean levels of major risk for microalbuminuria were low in our study. However, the prevalence of microalbuminuria in our subjects exceeded 45% at risk levels similar to those in the DEMAND and MAP studies (systolic blood pressure 140 mmHg or A1C 7.5%) [data not shown]. This indicates that the Japanese type 2 diabetic population may be susceptible to developing microalbuminuria. More strict control of blood pressure and A1C is needed for reducing UAE, for instance, by incorporating more ARBs/ACE inhibitors and diuretics, which were prescribed, respectively, to only 33 and 9% of Japanese patients, rates lower than those for Caucasians (58 and 29%, respectively) (5).
About 40% of patients had no ACR measurements regardless of the recommendation. There was a variation among the clinics in the frequency of ACR measurements, while the distribution of nephropathy stages did not differ. Alternatively, we should acknowledge that a few patients did not undergo UAE determination in daily practice. Such investigations have never been done, but this might be the case in other Asian or Western countries. The actual prevalence of microalbuminuria is considered even higher if we take nonattending diabetic patients into account.
Intervention studies with ARB (18), pioglitazone (19, 20) , and acarbose (20 -22) have yielded a reduction not only in UAE but also in cardiovascular morbidity. The facts would emphasize the importance of multifactorial treatment for modifiable risks aiming at reducing UAE and associated risks.
